On the analyst front, Oppenheimer maintained its Outperform rating for DexCom amid recent developments in the CGM market, while Redburn-Atlantic initiated coverage with a Neutral rating, setting a price target for DexCom shares at $130.00. Both firms highlighted the potential market opportunity for DexCom's products, given the large untapped market segments beyond intensive insulin users. However, they also noted future growth may come with higher risks due to competition and pricing pressures.